Argenx Se (ARGX) Current Assets (2015 - 2026)
Argenx Se's (ARGX) quarterly Current Assets came in at $8.1 billion in Q2 2026, down 99.86% YoY from $5829.7 billion in Q2 2025, and up 16.94% on a QoQ basis from $6.9 billion in Q4 2025.
Analysis
Argenx Se (ARGX) Current Assets (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Current Assets data on file, last reported at $8.1 billion in Q2 2026.
- Quarterly Current Assets fell 99.86% year-over-year to $8.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.1 billion (down 99.86% YoY) and the FY2025 annual result came in at $6.9 billion, up 41.28% from the prior year.
- Current Assets improved to $8.1 billion in Q2 2026, from $6.9 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $5829.7 billion in Q2 2025 to a low of $2.7 billion in Q2 2023.
- A 5-year average of $651.8 billion and a median of $4.3 billion in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2025 — Current Assets soared 136626.76% — and 2026, when it slumped 99.86%.
- Tracing ARGX's Current Assets over 5 years: stood at $2.8 billion in 2022, then soared by 48.65% to $4.1 billion in 2023, then climbed by 18.41% to $4.9 billion in 2024, then jumped by 41.28% to $6.9 billion in 2025, then gained by 16.94% to $8.1 billion in 2026.
- The last three Current Assets figures came in at $8.1 billion (Q2 2026), $6.9 billion (Q4 2025), and $5829.7 billion (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.82 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.03 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7.22 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.76 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 6.03 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.07 Bn |
| Dec 31, 2025 | 6.90 Bn |
| Jun 30, 2025 | 5,829.74 Bn |
| Dec 31, 2024 | 4,883.10 Bn |
| Jun 30, 2024 | 4.26 Bn |
| Dec 31, 2023 | 4.12 Bn |
| Jun 30, 2023 | 2.69 Bn |
| Dec 31, 2022 | 2,774.20 Bn |
| Jun 30, 2022 | 2.93 Bn |
| Dec 31, 2021 | 2,542.97 Bn |
| Jun 30, 2021 | 2.86 Bn |
| Dec 31, 2020 | 1,998.65 Bn |
| Jun 30, 2020 | 2.16 Bn |
| Dec 31, 2019 | 1.52 Bn |
| Jun 30, 2019 | 1.08 Bn |
| Dec 31, 2018 | 653.38 Mn |
| Jun 30, 2018 | 424.58 Mn |
| Dec 31, 2017 | 431.89 Mn |
| Jun 30, 2017 | 200.02 Mn |
| Dec 31, 2016 | 109.91 Mn |